Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Severe Complications from an Unexpectedly High Serum Mycophenolic Acid Concentration in a Patient with Renal Failure Secondary to Lupus Nephritis: A Case Report.

Doi Y, Kitayama H, Yamada M, Miyama Y.

Case Rep Nephrol Dial. 2019 Jun 4;9(2):72-78. doi: 10.1159/000500516. eCollection 2019 May-Aug.

2.
3.

Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen.

Fujinaga S, Ohtomo Y, Hara S, Umino D, Someya T, Shimizu T, Kaneko K.

Pediatr Nephrol. 2008 Oct;23(10):1877-82. doi: 10.1007/s00467-008-0800-7. Epub 2008 Apr 15.

PMID:
18414900
4.

Mycophenolate mofetil therapy in lupus nephritis: clinical observations.

Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA.

J Am Soc Nephrol. 1999 Apr;10(4):833-9.

5.

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, Hooi LS, Brunetta P, Maciuca R, Solomons N.

Clin J Am Soc Nephrol. 2013 Jan;8(1):147-53. doi: 10.2215/CJN.03290412. Epub 2012 Aug 9. Review.

7.

Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.

Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A.

J Rheumatol. 2001 Sep;28(9):2103-8.

PMID:
11550982
8.

Immunosuppressive treatment for proliferative lupus nephritis.

Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF.

Cochrane Database Syst Rev. 2018 Jun 29;6:CD002922. doi: 10.1002/14651858.CD002922.pub4. Review.

9.

Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.

Kamanamool N, Ingsathit A, Rattanasiri S, Ngamjanyaporn P, Kasitanont N, Chawanasuntorapoj R, Pichaiwong W, Anutrakulchai S, Sangthawan P, Ophascharoensuk V, Avihingsanon Y, Sumethkul V.

Lupus. 2018 Apr;27(4):647-656. doi: 10.1177/0961203317739131. Epub 2017 Nov 6.

PMID:
29105558
11.

Treatment of Class IV Lupus Nephritis with Mycophenolate Mofetil Monotherapy.

Nawata T, Kubo M, Fujii S, Shiragami K, Ikegami T, Kobayashi S, Hisano S, Yano M.

Intern Med. 2018 Jul 15;57(14):2067-2070. doi: 10.2169/internalmedicine.0304-17. Epub 2018 Feb 28.

12.

Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis.

Feng L, Deng J, Huo DM, Wu QY, Liao YH.

Nephrology (Carlton). 2013 Feb;18(2):104-10. doi: 10.1111/nep.12006. Review.

PMID:
23113811
13.

Mycophenolate mofetil for remission induction in severe lupus nephritis.

Cross J, Dwomoa A, Andrews P, Burns A, Gordon C, Main J, Mathieson P, O'Donoghue D, Jayne D; Renal Association Clinical Trials Subcommittee.

Nephron Clin Pract. 2005;100(3):c92-100. Epub 2005 Apr 11.

PMID:
15824513
14.

Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.

Lui SL, Tsang R, Wong D, Chan KW, Chan TM, Fung PC, Lai KN.

Lupus. 2002;11(7):411-8.

PMID:
12195781
15.

Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.

Sahin GM, Sahin S, Kiziltas S, Masatlioglu S, Oguz F, Ergin H.

Ren Fail. 2008;30(9):865-9. doi: 10.1080/08860220802353843.

PMID:
18925525
16.

Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study.

Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM.

Arthritis Res Ther. 2010;12(6):R208. doi: 10.1186/ar3184. Epub 2010 Nov 9.

17.

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; MAINTAIN Nephritis Trial Group.

Ann Rheum Dis. 2010 Dec;69(12):2083-9. doi: 10.1136/ard.2010.131995. Epub 2010 Sep 10.

18.

Mycophenolate mofetil for lupus nephritis: an update.

Mok CC.

Expert Rev Clin Immunol. 2015;11(12):1353-64. doi: 10.1586/1744666X.2015.1087314. Epub 2015 Sep 12. Review.

PMID:
26364748
19.

Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.

Feng X, Gu F, Chen W, Liu Y, Wei H, Liu L, Yin S, Da Z, Sun L.

Chin Med J (Engl). 2014;127(21):3718-23.

PMID:
25382325
20.

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.

Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS.

Rheumatology (Oxford). 2009 Aug;48(8):944-52. doi: 10.1093/rheumatology/kep120. Epub 2009 Jun 3.

PMID:
19494179

Supplemental Content

Support Center